文献速递心血管技术与安全PETCTUS

18F-氟贝他吡与68Ga-FAPI-04分子分层提高轻链型心脏淀粉样变性预后精准度

Molecular Stratification of Light-Chain Cardiac Amyloidosis With 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic Precision.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-01-08

这项前瞻性研究纳入38例确诊AL型心脏淀粉样变性患者,行超声心动图及18F-氟贝他吡与68Ga-FAPI-04 PET/CT显像,量化心脏淀粉样负荷与成纤维细胞激活。中位随访24.8个月期间13例死亡,较高的68Ga-FAPI-04心脏成纤维细胞激活蛋白体积(CFV)与总心脏成纤维细胞激活蛋白(TCF)与总生存期缩短相关,尤其在Mayo III期;多变量分析中较高TCF是总生存期缩短的主要决定因素。

要点

  • 68Ga-FAPI-04 PET/CT测得较高TCF与AL-CA患者总生存期缩短相关,多变量分析中为主要决定因素。
  • 全部38例均有淀粉样沉积,86.8%(33/38)显示心脏成纤维细胞激活。
  • 心脏淀粉样负荷与Mayo分期及多项超声心动图指标相关(P < 0.05)。

核心结论

  • 新诊断AL-CA患者中,68Ga-FAPI-04 PET/CT上较高的TCF可能是临床结局较差的相關因素,该指标似乎是18F-氟贝他吡显像的补充性分子影像工具,两者结合可能有助于全面理解分子特征并辅助临床决策。

研究设计与样本

  • 前瞻性研究,纳入38例确诊AL-CA患者(中位年龄58岁,76.3%男性),行超声心动图及18F-氟贝他吡与68Ga-FAPI-04 PET/CT显像,计算PET/CT指标与临床及超声心动图标志物的相关性并评估其与总生存期的关联。

关键影像表现/征象

  • 全部38例患者均显示淀粉样沉积,86.8%(33/38)显示心脏成纤维细胞激活。
  • 心脏淀粉样负荷以18F-氟贝他吡心脏淀粉样体积和总心脏淀粉样定量,与Mayo分期及多项超声心动图指标相关(P < 0.05)。
  • CFV与N末端B型利钠肽原水平相关(P < 0.05)。

诊断标准与关键数值

  • 心脏淀粉样负荷量化指标为18F-氟贝他吡心脏淀粉样体积和总心脏淀粉样。
  • 心脏FAP量化指标为68Ga-FAPI-04 CFV和TCF。
  • 中位随访24.8个月期间13例死亡;较高CFV和TCF与总生存期缩短相关,尤其在Mayo III期;多变量分析中较高TCF是总生存期缩短的主要决定因素。

临床应用与阅片要点

  • 作者认为68Ga-FAPI-04 PET/CT上较高TCF可能是新诊断AL-CA临床结局较差的相關因素,该指标似乎是18F-氟贝他吡显像的补充性分子影像工具。
  • 作者认为两种显像结合可能提供对分子特征的全面理解,辅助临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Cardiac involvement in amyloid light chain (AL) amyloidosis significantly influences prognosis, necessitating timely diagnosis and meticulous risk stratification.

OBJECTIVES: This prospective study aimed to delineate the molecular phenotypes of AL-cardiac amyloidosis (CA) by characterizing fibro-amyloid deposition using 18F-florbetapir and gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI)-04 positron emission tomography (PET)/computed tomography (CT) imaging. The authors also proposed a novel molecular stratification methodology for prognosis.

METHODS: Patients with confirmed AL-CA underwent echocardiography and 18F-florbetapir and 68Ga-FAPI-04 PET/CT imaging. Cardiac amyloid burden was quantified as 18F-florbetapir cardiac amyloid volume and total cardiac amyloid. Meanwhile, cardiac fibroblast activation protein (FAP) was quantified as 68Ga-FAPI-04 cardiac fibroblast activation protein volume (CFV) and total cardiac fibroblast activation protein (TCF). PET/CT metrics were calculated in correlation to clinical and echocardiographic markers and their association with overall survival (OS) evaluated.

RESULTS: Among the 38 patients enrolled (median age: 58 years; 76.3% male), all patients exhibited amyloid deposition, and 86.8% (33 of 38) patients exhibited cardiac fibroblast activation. Cardiac amyloid burden was correlated with Mayo stage and several echocardiography metrics (P < 0.05). In addition, there was a correlation between CFV and N-terminal pro-B-type natriuretic peptide level (P < 0.05). Thirteen deaths occurred over a median follow-up of 24.8 months. Higher CFV and TCF were associated with shortened OS, particularly in Mayo stage III. In multivariable analysis, higher TCF was a primary determinant for shortened OS.

CONCLUSIONS: The study underscores that higher TCF on 68Ga-FAPI-04 PET/CT imaging might be a correlated factor of worse clinical outcome in newly diagnosed AL-CA, and this metric seems to be a molecular imaging tool complementary to 18F-florbetapir imaging. The combination might offer a holistic understanding of molecular attributes, assisting in clinical decision-making.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Wang X, Shen K, Zhang Y, et al. Molecular Stratification of Light-Chain Cardiac Amyloidosis With 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic Precision. JACC Cardiovasc Imaging. 2025. PMID: 39797876. doi:10.1016/j.jcmg.2024.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。